Ruirong Ye

Dr. Ruirong Ye

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
ZZZaigang Zhou
Zaigang Zhou
NJNing Jiang
Ning Jiang
JCJiashe Chen
Jiashe Chen
CZChunjuan Zheng
Chunjuan Zheng
YGYuanyuan Guo
Yuanyuan Guo
JSJianliang Shen
Jianliang Shen
Background: Mild-temperature photothermal therapy (mild-PTT) has emerged as a highly promising antitumor strategy by triggering immunogenic cell death (ICD) to elicit both innate and adaptive immune responses for tumor control. However, mild-PTT still leads to the risk of tumor recurrence or metastasis because it could hardly completely eradicate tumors due to its impaired immunological efficacy owing to the enhanced PD-L1 expression in tumor cells after treatment. Results: In this study, we described a hydrogen peroxide (H2O2) responsive manganese dioxide mineralized albumin nanocomposite loading with mitochondria function inhibitor phenformin (PM) and near-infrared photothermal dye indocyanine green (ICG) by modified two-step biomineralization method. In combination with ICG induced mild-PTT and PM mediated mitochondria dysfunction, PD-L1 expression was obviously down-regulated and the generated immunological responses was able to effectively attack the remaining tumor cells. Meanwhile, the risk of tumor metastasis was effectively inhibited by reducing the expression of tumor invasion-related signal molecules (TGF-β and vimentin) after combining treatment. Conclusion: Such a strategy offers novel insight into the development of nanomedicine for mild-PTT as well as cancer immunotherapy, which can provide protection against tumor relapse post elimination of their initial and metastatic tumors. Graphical

1 October 2021 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
RYRuirong Ye
Ruirong Ye
BCBi-Chun Chen
Bi-Chun Chen
JLJun-Jian Lu
Jun-Jian Lu
XMXiu-Rong Ma
Xiu-Rong Ma
RLRongtao Li
Rongtao Li

1 February 2020 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
WPWan Peng
Wan Peng
AHAhmed M. Hegazy
Ahmed M. Hegazy
NJNing Jiang
Ning Jiang
XCXi Chen
Xi Chen
HQHua-Xin Qi
Hua-Xin Qi
RLRongtao Li
Rongtao Li

16 August 2022 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
XMXiurong Ma
Xiurong Ma
JLJunjian Lu
Junjian Lu
PYPeixin Yang
Peixin Yang
ZZZheng Zhang
Zheng Zhang
BHBo Huang
Bo Huang
RYRuirong Ye
Ruirong Ye
As an ideal scaffold for metal ion chelation, 8-hydroxyquinoline (8HQ) can chelate different metal ions, such as Fe2+, Cu2+, Zn2+, etc. Here, by integrating 8HQ with a ruthenium(II) polypyridyl moiety, two Ru(II)-8HQ complexes (Ru1 and Ru2), [Ru(N–N)2L](PF6)2 (L = 2-(1H-imidazo[4,5-f][1,10]phenanthrolin-2-yl)quinolin-8-ol; N–N: 2,2′-bipyridine (bpy, in Ru1), 1,10-phenanthroline (phen, in Ru2)) were designed and synthesized. In both complexes, ligand L is an 8HQ derivative designed to chelate the cofactor Fe2+ of jumonji C domain-containing demethylase (JMJD). As expected, Ru1 and Ru2 could inhibit the activity of JMJD by chelating the key cofactor Fe2+ of JMJD, resulting in the upregulation of histone-methylation levels in human lung cancer (A549) cells, and the upregulation was more pronounced under light conditions. In addition, MTT data showed that Ru1 and Ru2 exhibited lower dark toxicity, and light irradiation could significantly enhance their antitumor activity. The marked photodynamic activities of Ru1 and Ru2 could induce the elevation of reactive oxygen species (ROS), depolarization of mitochondrial membrane potential (MMP), and activation of caspases. These mechanistic studies indicated that Ru1 and Ru2 could induce apoptosis through the combination of JMJD inhibitory and PDT activities, thereby achieving dual antitumor effects.

28 April 2010 in Journal of Polymer Research
Verified
Journal Article
Closed access
PDF file
ZWZhaoyang Wang
Zhaoyang Wang
YLYu-Fen Luo
Yu-Fen Luo
RYRuirong Ye
Ruirong Ye
XSXiu-Mei Song
Xiu-Mei Song

26 May 2020 in Metallomics
Verified
Journal Article
Closed access
PDF file
RYRuirong Ye
Ruirong Ye
WPWan Peng
Wan Peng
BCBi-Chun Chen
Bi-Chun Chen
NJNing Jiang
Ning Jiang
XCXuan-Qin Chen
Xuan-Qin Chen
RLRongtao Li
Rongtao Li
Hepatocellular carcinoma (HCC) poses a serious threat to people’s health worldwide. Artesunate (ART), one of the classical antimalarial drugs, has recently been shown to exert significant cytotoxicity in various cancers, but its bioavailability is low. Cyclometalated iridium(iii) complexes have emerged as a promising class of anticancer therapeutic agents. Herein, through conjugation of two of them, three novel Ir(iii)–ART conjugates, [Ir(C–N)2(bpy-ART)](PF6) (bpy = 2,2′-bipyridine, C–N = 2-phenylpyridine (ppy, Ir-ART-1), 2-(2-thienyl)pyridine (thpy, Ir-ART-2), and 2-(2,4-difluorophenyl)pyridine (dfppy, Ir-ART-3)) have been synthesized, and their potential as anti-HCC agents was evaluated. We demonstrate that Ir-ART-1–3 display higher cytotoxicity against HCC cell lines than normal liver cells, and they can especially locate to mitochondria of HepG2 cells and induce a series of mitochondria-mediated apoptosis events. Moreover, Ir-ART-1–3 can regulate the cell cycle and inhibit metastasis of HepG2 cells. Finally, in vivo antitumor evaluation also demonstrates the inhibitory activity of Ir-ART-1 on tumor growth. Taken together, these Ir(iii)–ART conjugates have the potential to become drug candidates for future anti-HCC treatments.